Court Blocks NIH Cap on Indirect Cost Rates for Government Contracts In a significant development for research institutions and federal contractors, a federal judge has temporarily blocked the National Institutes of Health (NIH) from enforcing its cap on indirect cost rates. This decision comes as a result of a temporary restraining order (TRO) issued by […]
Court Blocks NIH Cap on Indirect Cost Rates Read More »
Lithium Ion Battery Development Overview of the Solicitation The Department of Energy (DOE) and affiliates have released a Request for Proposals (RFP) for the development of a safe lithium-ion battery. This initiative aims to create a backup energy storage system capable of providing 2.4 MW*hrs of usable energy while ensuring a robust safety posture. The
Safe Lithium-Ion Battery Development Read More »
Overview The National Institutes of Health (NIH) has issued Supplemental Guidance to the 2024 NIH Grants Policy Statement regarding Indirect Cost Rates (NOT-OD-25-068). This update introduces a standardized 15% indirect cost rate for all applicable grants, aiming to streamline financial policies and enhance funding efficiency for research institutions. Purpose of the Guidance The primary objective
Understanding the NIH Supplemental Guidance on Indirect Cost Rates Read More »
On January 27 and January 28, the Office of Management and Budget (OMB) issued guidance as follows: Memorandum M-25-13, an executive directive halting all federal financial assistance programs as agencies reevaluate spending priorities. An Excel file titled Federal Financial Assistance Program Analysis Template Additional Guidance with Q&A OMB Memorandum M-25-13 Published on January 27, 2025,
DARPA, Microsystems Induced CAtalysis (MICA) Program Overview of the MICA Program The Defense Advanced Research Projects Agency (DARPA) has recently announced a groundbreaking funding opportunity, titled “Microsystems Induced CAtalysis” (MICA). This Broad Agency Announcement (BAA) aims to enhance molecular science by creating advanced tools and techniques for controlling molecular catalysts using microsystems. This initiative goes
Unlocking the Future of Microsystems: DARPA’s MICA Program Read More »
Amendment 034 – DRIVe EZ BAA_ReBooT_RePAIR New Opportunities with DRIVe: ReBooT and RePAIR Amendments The Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation & Ventures (DRIVe) has announced updates to its Easy Broad Agency Announcement (EZ-BAA) with Amendment #034. This amendment reopens and revises the ReBooT (AOI #22) program and pauses the
New Opportunities with DRIVe: ReBooT and RePAIR Amendments Read More »
What to Expect in the Webinar: Federal Programs at Risk: Explore which key life sciences programs might face funding challenges in a new Trump administration. Emerging Opportunities: Learn about research areas poised to gain new momentum and potential funding in the evolving political landscape. Key Players Shaping Change: Get insights into the policymakers and influencers
Webinar Alert: R&D Funding in Life Sciences: What’s Ahead in Trump 2.0? Read More »
Securing federal funding is more than a financial boost – it’s a strategic move that positions your company as a leader in innovation. EverGlade Consulting’s proven process helps small and medium-sized AI and tech firms navigate complex federal funding landscapes. Our process works because we focus on your business goals, not just technical details, ensuring
Unlocking Federal Opportunities for AI & Technology Innovators Read More »
Congress’s passage of a continuing resolution (CR) has averted a shutdown and provided temporary relief until late March. However, this short-term fix exposes significant gaps in public health and technology preparedness that demand immediate attention. As critical programs approach expiration and threats beyond the Pandemic and All-Hazards Preparedness Act (PAHPA) remain unresolved, lawmakers have a
After the CR: Funding Opportunities and Gaps in Pandemic Preparedness Read More »
EverGlade Consulting, a national consulting firm, has helped SonALAsense successfully secure up to $46 million in funding to develop a minimally or non-invasive ultrasound treatment to activate a compound that can destroy cancer cells. Improving Patient Outcomes The $46 million in ARPA-H funding, announced as part of ARPA-H’s initiative to revolutionize cancer treatment through cutting-edge
EverGlade Consulting Helps SonALAsense Secure up to $46 Million in ARPA-H Funding Read More »
PrEP_Solicitation_Nucleic_Acid_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of long-acting nucleic acid-based platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The specific goals of these PrEP DEV awards include
RPP-24-02-ODM The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at the preparation for and response to public health emergencies through On-Demand Manufacturing. The RPP, numbered 24-02-ODM, focuses advancing manufacturing technologies that will improve access and enable faster, cheaper, more rapid, and flexible production of vaccines
BARDA Issues RPP for On-Demand Manufacturing Read More »
